X

Due to the lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

Updates regarding government operating status and resumption of normal operations can be found at http://www.usa.gov.
NOT-FD-14-010: Notice of Change to Extend the Application Due Date, Expiration Date, Anticipated Number of Awards and Award Project Period for RFA-FD-14-016 "Evaluation of In Vitro Release Methods for Liposomal Drug Products (U01)"
Notice of Change to Extend the Application Due Date, Expiration Date, Anticipated Number of Awards and Award Project Period for RFA-FD-14-016 "Evaluation of In Vitro Release Methods for Liposomal Drug Products (U01)"

Notice Number: NOT-FD-14-010

Key Dates
Release Date: May 20, 2014

Related Announcements
RFA-FD-14-016

Issued by
Food and Drug Administration (FDA)

Purpose

This Notice of Change is to inform potential applicants of changes to the published RFA-FD-14-016 "Evaluation of in Vitro Release Methods for Liposomal Drug Products (U01)" as indicated below:

Key Dates are changed as follows: The Application Due Date is extended to June 15, 2014, by 5:00 PM local time of applicant organization. Expiration Date has changed to June 16, 2014.

Section II. Award Information is changed as follows:

Funds Available and Anticipated Number of Awards:  The FDA and partner components intend to commit $500,000 per award. Awards are contingent upon the availability of funds. Future year amounts will depend on annual appropriations and performance.

Award Project Period:  The scope of the proposed project should determine the project period.  The maximum project period is 2 year.

All other aspects of the FOA remain unchanged.

Inquiries

Please direct all inquiries to:

Nan Zheng
Food and Drug Administration (FDA)
Telephone: 240-402-7972
Email: Nan.Zheng@fda.hhs.gov